Blood Brain Barrier (BBB) permeability is frequently compromised in the course of diseases affecting the central nervous system (CNS). Sucrose is a low molecular weight, hydrophilic marker with low permeability at the naive BBB and therefore one of the widely used indicators of barrier integrity. Our laboratory recently developed a highly sensitive UPLC-MS/MS method for stable isotope labelled [ 13 C 12 ]sucrose in biological matrices. Correction of total brain concentration for contribution of intravascular space is required in such experiments in order to accurately measure BBB permeability, and it is often accomplished by vascular perfusion with buffer solutions prior to brain sampling. The purpose of the present study was to develop a UPLC-MS/MS method, which allows simultaneous analysis of two different stable isotope labeled sucrose variants, one of which can be utilized as a vascular marker. The first analyte, [ 13 C 12 ]sucrose, serves to quantify brain uptake clearance as a measure of BBB permeability, while the second analyte, [ 13 C 6 ]sucrose, is administered just before termination of the animal experiment and is considered as the vascular marker. [ 2 H 2 ]sucrose is used as the internal standard for both 13 C labeled compounds. Because the majority of recent studies on CNS diseases employ mice, another objective was to validate the new technique in this species. The UPLC-MS/MS method was linear (r 2 ≥0.99) in the tested concentration ranges, from 10 to 1,000 ng/mL for both analytes in plasma, from 2 to 400 ng/g [ 13 C 12 ]sucrose in brain and from 10 to 400 ng/g [ 13 C 6 ]sucrose in brain. It was also validated in terms of acceptable intra and inter run accuracy and precision values (n=5). The dual analyte technique was applied in a study in mice.
Introduction
The microenvironment within the central nervous system (CNS) needs to be tightly controlled for optimal function, because the composition of CNS extracellular fluid (also known as cerebrospinal fluid) is unique when compared to other tissues. The precise control of substances entering or leaving the CNS is maintained by the blood-brain barrier (BBB) [1, 2] .
With the help of complex intercellular tight junctions between the endothelial cells, the BBB effectively restricts the passage of ions and polar compounds, resulting in high transendothelial electrical resistance and low paracellular permeability [3] . Impairment of the BBB is either the cause or a major pathophysiological consequence of many diseases affecting the CNS (i.e., ischemic stroke, neuroinflammatory and neurodegenerative disorders). Therefore, BBB permeability is considered one of the important parameters to be monitored in experimental and clinical studies of CNS disorders [4] [5] [6] .
A range of BBB permeability markers is currently in use in experimental animal models, including Evans Blue, sodium fluorescein, horseradish peroxidase, sucrose, and inulin [7] [8] [9] .
Among the drug-like low molecular weight agents, radiolabeled sucrose (e.g. [ 14 C]sucrose) has long been considered the most accurate marker, explaining its frequent use [9] . We have recently introduced [ 13 C 12 ]sucrose as a superior marker substance, which is non-radioactive and can be quantified by a sensitive and highly specific LC-MS/MS technique [10] [11] [12] . The [ 13 C 12 ]sucrose technique has previously been validated in rats in our laboratory [10] . For an accurate measurement of the concentrations of the marker in the brain tissue, the method relies on removal of the marker from the brain vasculature by a brief vascular washout by transcardiac perfusion with buffer solution before tissue sampling. However, it is difficult to judge the completeness of vascular washout in an individual animal. Additionally, there are numerous variations in technical details how the perfusions are performed, e.g., with regard to total volume, duration, flow rate, temperature and composition of perfusion fluid, which may add to the experimental variability.
An alternative is to include a second marker in the brain uptake experiments, which is injected just prior to the terminal sampling time. Although the application of a vascular marker that is physicochemically identical to the primary analyte has been advocated in the earlier BBB literature [13] , emulation of this approach is rare and only few practical applications exist to date, likely due to the experimental effort required for any given analyte to reduce the concept to practice. Go and Pratt analyzed brain uptake of sodium ions using two radioisotopes with vastly different physical half-lives ( 22 Na and 24 Na), which allowed discrimination of the fractions of the two isotopes present in a tissue sample [14] . In an example from the other end of the molecular weight spectrum, Poduslo's laboratory corrected the brain uptake of macromolecules by radioiodinating the same protein with either 125 I or 131 I, and one labeled species was used as a vascular marker [15] .
The commercial availability of different stable isotope labeled versions of sucrose allows their simultaneous use as both the BBB permeability and brain vascular space markers. Therefore, the main purpose of this study was to develop a UPLC-MS/MS method to utilize one variant of [ 13 C]sucrose as the permeability marker, another [ 13 C]sucrose version as the vascular marker, and a third, deuterium labeled sucrose, as the internal standard. Selecting suitable combinations of mass transitions and settings of the mass detector allows simultaneous LC-MS/MS quantification of the three sucrose variants, which co-elute at the identical retention time from a BEH-amide UPLC column. Because mice are currently the most frequently used rodent model for studying the BBB, a secondary objective of our study was to validate the technique for use in mice, as opposed to our previous method for the use of [ 13 C]sucrose in rats. Applying this approach in mice, we show that the brain concentration and permeability values of sucrose can be corrected equally well as achieved by buffer washout.
2.
Materials and methods 
Chemicals and reagents

Animals
Female C57Bl/6 mice, 8-10 weeks of age, body weight 24-27 g, were supplied by Jackson Laboratories (Bar Harbor, ME, USA) and used in the pharmacokinetic study. Mice had free access to standard rodent chow and water and were housed in an AAALAC-accredited animal facility under controlled humidity and temperature conditions with a 12h light/12h dark cycle.
The experimental protocols were approved by the Institutional Animal Care and Use Committee at Texas Tech University Health Sciences Center and conformed to current NIH guidelines.
Mass spectrometric and chromatographic conditions
Analyte detection was performed using an AB SCIEX QTRAP® 5500 triple quadrupole mass spectrometer (MS) attached to a Nexera UPLC system (Shimadzu Corporation). Electrospray ionization in negative mode was used as the ionization source.
Optimization of mass spectrometer parameters for [ 13 C 12 ]sucrose and [ 13 C 6 ]sucrose was already shown in our previous study [10] . individual plasma calibration standards were then diluted 100-fold with water to produce concentrations within the range of 10-1,000 ng/mL, before being subjected to the sample preparation procedure detailed below. In case of the brain standard curve, blank brain tissue was homogenized in water (1:9) and both analytes were spiked into the homogenate to obtain concentrations ranging from 2 to 400 ng/mL for [ 13 C 12 ]sucrose and 10 to 400 ng/ml for
Sample preparation
As mentioned above, plasma calibration standards and unknown samples were diluted 100 times with LC-MS/MS grade water, and brain samples were homogenized in water (1:9) before analysis. Deproteination for all samples was achieved in a microcentrifuge tube by diluting at a ratio of 1:9 in acetonitrile: water (80:20) containing 10 ng/mL of internal standard.
Precipitated samples were vortexed, followed by centrifugation at 20,000 g for 10 minutes. The supernatant was transferred into autosampler inserts. A sample volume of 5 µL was injected onto the UPLC column.
Method validation 2.6.1. Selectivity
Selectivity of the method was ensured by running blank matrix samples containing no analyte. Also in order to ensure that there is no interference in among the analyte transitions, neat samples containing single analytes without any matrix prepared in mobile phase composition were run using the method defined above.
Accuracy and precision
The accuracy and precision of the method was determined through inter and intra-day runs, where quality control samples were evaluated against calibration curves. For calculation, five repeats of low, medium, and high concentrations were analyzed. The accuracy was calculated as percentage of measured concentration over nominal concentration. Precision was calculated as percentage of relative standard deviations (R.S.D.). The acceptable inter and intrarun limits for the accuracy were set at 85-115% for the middle and high concentrations and 80-120% for the low concentration. The acceptable precision values were 15% (medium and high concentrations) or 20% (low concentration) [16] .
Linearity
The linearity of calibration curves was evaluated by the coefficient of variation (r 2 ) of the linear regression analysis of the concentration-response data using a weight of 1/x, where x is the concentration. Weighting by 1/x is superior to analysis with equal weights, because the latter results in greatly diminished accuracy and high variability at low concentrations.
Recovery
Recovery of the analytes was checked and found not to be subject to matrix effects in the previously developed method for both [ 
Freeze thaw stability
We subjected neat samples of the analytes at a concentration of 500 ng/mL to three freeze/thaw cycles. Samples were stored at -80°C and thawed at room temperature for one hour, replicating experimental conditions. Concentration of the analytes in the neat samples was compared against a standard curve.
2.6.6 Long-term, storage stability of unprocessed and short-term stability of processed samples Long term, storage stability was checked for the diluted plasma samples and brain homogenates at -80°C. Quality control samples at low, medium, and high concentrations of analytes in the brain and plasma (n = 3) were stored at -80°C for one month and 5 months, respectively. The stored samples were then compared against standards in order to assess stability. Similarly, for the processed sample stability, quality control samples in both matrices (n = 3) were subjected to the sample preparation method above, and the supernatant after protein precipitation was stored at 4°C for 24 hours before injection by the autosampler.
Application of the method
A pharmacokinetic study was conducted in two groups of anesthetized C57BL/6 mice.
Isoflurane (4% for induction, 1.5-2% v/v for maintenance) in 70% nitrous oxide / 30% oxygen at a flow rate of 1 L/min was applied via a silicone face mask. The jugular veins were bilaterally exposed by skin incisions at the neck for IV injections on one side and blood sampling from the contralateral side. (1) Values for brain uptake clearance, K in , also known as the permeability-surface area product, were calculated using the following equation [17] based on either uncorrected ( ) 12 or corrected ( ) brain concentrations of [ 13 C 12 ]sucrose: Figure 1 depicts the mass spectra with precursor and product ions for [ 13 [10] , the mass spectra obtained for the 2 13 C-labelled isotopes of sucrose showed m/z transitions of 353>92 and 347>89 for [ 13 C 12 ]sucrose ( Fig. 1a ) and [ 13 C 6 ]sucrose ( Fig.   1b ), respectively. In case of [ 13 C 6 ]sucrose, the m/z transition of 347>59 is also a viable alternative ( Fig. 1b) . For the newly optimized [ 2 H 2 ]sucrose, the m/z transition of 343>89 was found to be the best transition in terms of signal to noise ratio (Fig. 1c ). In the previously 
Results
MS parameter optimization of [ 2 H 2 ]sucrose
Selectivity
Single analyte neat samples prepared in water showed no cross-channel interference between transitions in the absence of matrix (Fig. 3) . Chromatograms of samples containing blank, lowest standards and internal standard in mouse plasma and mouse brain are depicted in Fig. 4 . The matrix samples were found to be acceptable without any interference except for transition 347>89 of [ 13 C 6 ]sucrose, which had an interfering peak in the blank brain samples at the same retention time as the analyte (approx. 2.1-2.2 min). The transition 347>59 had a peak at retention time approx. 2.6 minute in brain matrix, which does not interfere with the analyte peak at retention time of 2.1 min, and hence was chosen for measurement of brain samples.
Accuracy and precision
The results of the inter and intra run accuracy and precision experiments in plasma and brain samples are presented in Tables 1 and 2 , respectively. Accuracy and precision values of the quality control samples in low, middle and high-level QCs across both tested matrices were found to be within the acceptable limits.
Linearity
Calibration curves in both tested matrices across all intra and inter assay runs were found to be linear with r 2 >0.99.
Recovery
The recoveries (mean ± SD) of [ 13 
LLOD and LLOQ
As apparent from Fig. 4 and Tables 1 and 2 
Stability
Results from the long-term, storage stability of unprocessed and short-term stability of processed samples are shown in Table 3 . Additionally, Fig. 5 depicts the freeze thaw stability data. All data were found to be within specifications. Analytes were found to be stable in plasma and brain matrix over long term (Table 3) . Also, processed samples stability data suggest that the processed samples could be stored at 4 o C for up to 24 hours before analysis (Table 3) .
However, we found that at 48 hours the peak shape degraded, indicating a storage time of processed samples beyond 24 hours may not be suitable (data not shown).
Application of the method
The results of the pharmacokinetic study are depicted in Fig. 6 . All concentrations of analytes [ 13 C 12 ]sucrose or [ 13 C 6 ]sucrose measured from brain and plasma samples fell within the range of the respective standard curves. As expected, plasma concentration -time curves in the two groups of mice were similar (Fig. 6a) , and the areas under curve from 0 to 15 min were not significantly different (unpaired, two-tailed, t-test). After considering the dilution factor of Brain concentration of the BBB permeability marker [ 13 C 12 ]sucrose in the Washout group was 129 ± 26.0 ng/g; brain concentration of [ 13 C 12 ]sucrose in the Vascular Marker group was 265 ± 42 ng/g before correction for intravascular content, and 138 ± 27 ng/g after correction (see Fig.   6b ). Comparison of the corrected brain concentrations (washout vs. vascular marker correction) showed no significant difference (p = 0.59, unpaired, two-tailed t-test). Similarly, the values for brain uptake clearance, K in-corr , were almost identical under both techniques: 0.257 ± 0.053 µL min -1 g -1 vs. 0.260 ± 0.047 µL min -1 g -1 for the Washout and Vascular Marker groups, respectively, as depicted in Fig 6c. Without correction for the intravascular content, the estimate of apparent K in in the Vascular Marker group would be 0.501 ± 0.064 µL min -1 g -1 . The estimated intravascular plasma space, V 0 , as represented by the apparent volume of distribution of the vascular marker, was 9.12 ± 1.89 µL g -1 .
Discussion
The results of this study represent an extension and refinement of the previously described method [10] for measurement of [ 13 C 12 ]sucrose in brain and plasma by UPLC-MS/MS.
Sample preparation and quality control experiments demonstrated that measuring stable
labelled isotopes of sucrose in plasma and brain matrices from mice can be performed with similar assay quality as in rats [10] . Accuracy and precision values for the lowest calibration standard (Tables 1 and 2) , along with linearity of the standard curves, were all well within the defined specifications. Similar to previous findings [10, 18] , the recovery from the matrices throughout the concentration ranges covered by the standard curves was found to be almost quantitative for both [ 13 C 12 ] sucrose and [ 13 C 6 ]sucrose.
The dual analyte method with a vascular marker is particularly attractive in the case of sucrose, because several isotopically labelled variants of sucrose are readily commercially available. As they are chemically equivalent and co-elute from a suitable stationary phase, such as the BEH amide column used here, variation of detector signal due to confounding factors, like differences in ion suppression between analytes and/or internal standard, is expected to be minimal. As shown in Fig. 4 , equivalent mass transitions for all three sucrose isotopes can be chosen for analysis in the various matrices, with the exception of [ 13 C 6 ]sucrose in brain. Blank brain matrix showed a peak at the same retention time as the analyte at transition m/z 347>89.
Transition 347>59 m/z provided a better signal to noise ratio and was used for quantification of [ 13 C 6 ]sucrose in brain matrix. Since the in vitro stability of [ 13 C 12 ] sucrose in cell culture media as well as brain homogenate was tested in a previous study for up to 3 hours [12] , in this study we also included processed samples stability, long term stability as well as freeze thaw stability in order to confirm that the analytes stay stable in the applied conditions for specified periods of time. Since both analytes are different stable isotope labeled versions of the same molecule, we can imply that the stability for [ 13 C 12 ] sucrose is also valid for [ 13 C 6 ]sucrose.
We found that for physiological applications, such as brain uptake experiments, the dual analyte technique is equally effective as buffer perfusion. As demonstrated in the mice receiving a vascular marker injection, the intravascular content, if left uncorrected, would cause significant overestimation of brain concentration and K in by a factor of almost 2 in the present experiments with brain sampling at 15 min ( Fig. 6b and c) . At shorter terminal sampling time points that error would be even more pronounced, because plasma concentrations are still higher (Fig. 6a) , and therefore the ratio of vascular content to total brain concentration is also higher. Because the vascular marker itself is subject to brain uptake during the brief interval between injection and brain sampling, intravascular volume is slightly overestimated, and correspondingly, the calculated values of corrected brain concentration and K in for the permeability marker [ 13 C 12 ]sucrose, would be slightly underestimated. However, as shown by our data, that error is too small to result in significant differences when compared to the vascular washout procedure. Moreover, the V 0 value of 9.12 ± 1.89 µL g -1 , as measured with [ 13 C 6 ]sucrose in the present study, is almost identical to the brain plasma volume of 9.3 ± 1.1 µL g -1 as determined by our laboratory with radiolabeled IgG in a previous study in mice [19] , and it falls into the middle of the range of values reported in the literature for rodents [20] .
There are distinct practical advantages of the correction method by vascular marker administration over the washout method: It is technically simpler, and collection of brain tissue is feasible within seconds after the terminal blood sampling, rather than being delayed several minutes by thoracotomy and perfusion (e.g., over 10 min in the present study). Additionally, rapid sampling is important when, in addition to measurement of BBB permeability, parts of the brain samples were to be used for measurement of other analytes that may be subject to rapid degradation, such as neurotransmitters or metabolites.
Conclusions
been refined by the addition of a second stable isotope labeled sucrose variant, which serves as a vascular marker. The method allows measurement of both analytes in the same sample in a single run. This technique simplifies correction for intravascular plasma space in brain uptake experiments with sucrose and makes a vascular washout step dispensable. Table 3 Stability of [ 13 C 12 ]sucrose during long-term storage (5 months for plasma and 1 month for brain homogenate, -80°C) of unprocessed and short-term storage (24 hr for both plasma and brain homogenate, 4°C) of processed samples (n = 3). 
Long-term storage stability of unprocessed samples
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